最終更新日:2025/11/25
In the clinical trial, the novel antibody candidate abci-fung-umab significantly reduced invasive fungal burden in immunocompromised patients.
正解を見る
In the clinical trial, the novel antibody candidate abci-fung-umab significantly reduced invasive fungal burden in immunocompromised patients.
音声機能が動作しない場合はこちらをご確認ください
編集履歴(0)